ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away

4 hours ago 3

Jonathan Ponciano, The Motley Fool

Sun, December 28, 2025 astatine 11:46 AM CST 5 min read

Oregon-based Stonepine Capital Management sold each 38,597 shares of its ANI Pharmaceuticals shares successful the 3rd quarter.
The shares were worthy astir $2.52 million.
The determination marked a afloat exit from ANI, with the money reporting nary shares held arsenic of September 30.
These 10 stocks could mint the adjacent question of millionaires ›

On November 13, Oregon-based Stonepine Capital Management reported successful its latest SEC filing that it afloat exited its presumption successful ANI Pharmaceuticals (NASDAQ:ANIP), reflecting a $2.52 cardinal nett decrease.

According to a regulatory filing with the Securities and Exchange Commission dated November 13, Stonepine Capital Management sold its full presumption of 38,597 shares successful ANI Pharmaceuticals (NASDAQ:ANIP). The worth of the transaction, based connected mean quarterly prices, was $2.52 million.

Top holdings aft the filing:

NASDAQ:VSTM: $23.58 cardinal (19.17% of AUM)
NASDAQ:ADMA: $10.83 cardinal (8.81% of AUM)
NASDAQ:EOLS: $9.43 cardinal (7.67% of AUM)
NASDAQ:ZVRA: $7.70 cardinal (6.26% of AUM)
NASDAQ:NKTR: $4.84 cardinal (3.93% of AUM)

As of Friday, shares of ANI Pharmaceuticals were priced astatine $82.41, up 49% implicit the past twelvemonth and good outperforming the S&P 500, which is up astir 15% successful the aforesaid period.

Metric

Value

Market Capitalization	$1.85 billion
Revenue (TTM)	$826.89 million
Net Income (TTM)	$40.57 million
Price (as of Friday)	$82.41

ANI Pharmaceuticals develops, manufactures, and markets branded and generic medicine pharmaceuticals, with a absorption connected controlled substances, oncology products, hormones, steroids, injectables, and oral coagulated dose formulations.
The institution generates gross chiefly done the merchantability of proprietary and generic pharmaceuticals, arsenic good arsenic declaration improvement and manufacturing services for different pharmaceutical companies.
It serves retail pharmacy chains, wholesalers, distributors, message bid pharmacies, and radical purchasing organizations crossed the United States and Canada.

ANI Pharmaceuticals, Inc. operates arsenic a specialty and generic cause shaper with a diversified merchandise portfolio targeting niche therapeutic areas.

The institution manufactures some proprietary products and performs declaration improvement and manufacturing for different companies, serving a wide lawsuit basal including retail pharmacy chains, wholesalers, distributors, message bid pharmacies, and radical purchasing organizations.

ANI banal is acold from its aboriginal aughts peak, but the concern is present operating similar a scaled specialty pharma institution with existent net power, which changes however hazard gets priced.

The latest 4th underscored that shift. Third-quarter gross surged 54% twelvemonth implicit twelvemonth to $227.8 million, portion adjusted EBITDA jumped astir 70% to $59.6 million. Management raised full-year guidance again, present calling for up to $873 cardinal successful gross and arsenic overmuch arsenic $228 cardinal successful adjusted EBITDA, with uncommon illness therapies expected to thrust astir fractional of full income successful 2025. That benignant of maturation illustration is notable successful specialty pharma erstwhile a banal is already up astir 50% successful a year.

From a portfolio perspective, the exit looks little similar a ballot of nary assurance and much similar superior rotation. Stonepine’s remaining holdings skew toward earlier-stage biotech names wherever upside is little afloat priced, portion ANI has rerated into a much mature, execution-driven story. Ultimately, ANI’s fundamentals stay strong, but aboriginal returns volition apt hinge connected sustained uncommon illness maturation and borderline subject alternatively than aggregate expansion. At this level, patience matters much than momentum.